The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) announced the results of their review of 12 plants improved through genetic engineering techniques. APHIS found that the modified plants were unlikely to pose an increased plant pest risk compared with their non-modified counterparts.
The United States Food and Drug Administration (FDA) has approved Casgevy and Lyfgenia, the first cell-based gene therapies to treat sickle cell disease (SCD). Casgevy is the first FDA-approved treatment developed using CRISPR-Cas9 genome editing technology, signaling an innovative advancement in gene therapy.
Researchers from Nagoya University in Japan found that electric eels can release electricity to modify small fish larvae through electroporation. This gene delivery technique enables DNA or proteins to enter the target cells through intense electrical pulses.
Awareness-building activities have been the cornerstone of knowledge-sharing and capacity-building initiatives of various organizations in the country. These activities aim to promote an enabling environment for biotechnological innovations. As part of the ongoing efforts to promote biotech, ISAAA Inc. collaborated with the Biotechnology Coalition of the Philippines (BCP) to organize a webinar series about gene editing and gene drive. The first webinar, titled Gene Genies: Gene Editing by Filipino Scientists, is scheduled on January 22, 2024, at 10:00 AM GMT+8, while the second webinar on gene drive is planned for February 2024. The pre-registration is now open to all public high schools in the Philippines. Each school may submit names of five students and one teacher as participants.
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
Comments
Post a Comment